SEARCH

SEARCH BY CITATION

References

  • 1
    5th European Regulatory and Scientific Conference. New legislation update viewpoints of regulators and industry. Drug Inf J 2002; 36(Suppl.):S18.
  • 2
    Kaplan RM. The significance of quality of life in health care. Qual Life Res 2003;12(Suppl. 1):316.
  • 3
    Willke RJ, Burke LB, Erickson P. Measuring treatment impact. a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials 2004;25: 53552.
  • 4
    Apolone G, De Carli G, Brunetti M, Garattini S. Health-related quality of life (HR-QOL) and regulatory issues. An assessment of the European Agency for the Evaluation of Medicinal Products (EMEA) recommendations on the use of the HR-QOL measures in drug approval. Pharmacoeconomics 2001;19: 18795.
  • 5
    Acquadro C, Berzon R, Dubois D, et al. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health 2003;6: 52231.
  • 6
    European Commission. A guideline on summary of product characteristics. December 1999. (To be included in the rules governing medicinal products in the European community volume 2A and 2B The Notice to Applicants).
  • 7
    European Commission. Guideline on the packaging information of medicinal products for human use authorized by the community. May 2000. (To be included in the rules governing medicinal products in the European community the notice to applicants volume 2C Regulatory Guidelines).
  • 8
    Council Directive 92/27/EEC of 31 March 1992 on the labelling of medicinal products for human use and on package leaflets. OJ 30041992;113: 8.
  • 9
    International Conference on Harmonisation. Note for Guidance on Statistical Principles for Clinical Trials. ICH Topic E9. Geneva, Switzerland: International Conference on Harmonization, 1998.
  • 10
    EMEA. Note for guidance on statistical principles for clinical trials. ICH Topic E9. Statistical principles for clinical trials. CPMP/ICH/363/96. London, 1998.
  • 11
    EMEA. Note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use. CPMP/BPWG/283/00. London, 2002.
  • 12
    EMEA. Points to consider on clinical investigation of medicinal products for the treatment of acute stroke. CPMP/EWP/56/98. London, 2001.
  • 13
    EMEA. Points to consider on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis (ALS). CPMP/EWP/565/98. London, 2000.
  • 14
    EMEA. Points to consider on clinical investigation of medicinal products in the treatment of patients with chronic obstructive pulmonary disease (COPD). CPMP/EWP/562/98. London, 1999.
  • 15
    EMEA. Points to consider on clinical investigation of medicinal products for the management of chron's disease. CPMP/EWP/2284/99. London, 2001.
  • 16
    EMEA. Concept paper on the development of a committee for proprietary medicinal products (CPMP) points to consider on the evaluation of drugs for the treatment of irritable bowel syndrome. CPMP/EWP/785/97. London, 2000.
  • 17
    EMEA. Points to consider on clinical investigation of medicinal products in the treatment of osteoarthritis. CPMP/EWP/784/97. London, 1998.
  • 18
    EMEA. Points to consider on clinical investigation of slow acting anti-rheumatic medicinal products in rheumatoid arthritis. CPMP/EWP/556/95. London, 1998.
  • 19
    EMEA. Note for guidance on clinical development of medicinal products for treatment of allergic rhino-conjuctivitis. CPMP/EWP/2455/02. London, 2003.
  • 20
    EMEA. Note for guidance on medicinal products in the treatment of alzheimer's disease. CPMP/EWP/553/95 Corrected. London, 1997.
  • 21
    EMEA. Concept paper on the development of CPMP note for guidance on clinical investigation of medicianal products for the treatment of social anxiety disorder (social phobia). CPMP/EWP/3635/03. London, 2003.
  • 22
    EMEA. Note for guidance on the clinical investigation of medicinal products in the treatment of asthma. CPMP/EWP/2922/00 Draft. London, 2001.
  • 23
    EMEA. Note for guidance on evaluation of anticancer medicinal products in man. CPMP/EWP/205/95 Rev 2. London, 2001.
  • 24
    EMEA. Note for guidance on clinical investigation of medicinal products for the treatment of cardiac failure—addendum on acute cardiac failure. CPMP/EWP/2986/03. London, 2003.
  • 25
    EMEA. Note for guidance on the clinical investigation of medicinal products in the treatment of cardiac failure. Rev 1. CPMP/EWP/235/95. London, 1995.
  • 26
    EMEA. Note for guidance on clinical development of medicinal products for treatment of HIV infection. CPMP/EWP/633/02. London, 2003.
  • 27
    EMEA. Note for guidance on clinical investigation of medicinal products for the treatment of multiple sclerosis. CPMP/EWP/612/00 Draft. London, 2001.
  • 28
    EMEA. Note for guidance on clinical investigation of medicinal products for the treatment of obsessive compulsive disorder. CPMP/EWP/4279/02. London, 2003.
  • 29
    EMEA. Points to consider on clinical investigation of medicinal products in neuropathic pain. CPMP/EWP/252/03. London, 2003.
  • 30
    EMEA. Note for guidance on clinical investigation of medicinal products for treatment of nociceptive pain. CPMP/EWP/612/00. London, 2002.
  • 31
    EMEA. Note for guidance on clinical investigation of medicinal products indicated for the treatment of panic disorder. CPMP/EWP/4280/02. London, 2003.
  • 32
    EMEA. Note for guidance on clinical investigation of medicinal products in the treatment of Parkinson's Disease. CPMP/EWP/563/95. London, 1998.
  • 33
    EMEA. Note for guidance on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease. CPMP/EWP/714/98 Draft. London, 2000.
  • 34
    EMEA. Note for guidance on clinical investigation of medicinal products indicated for the treatment of psoriasis. CPMP/EWP/2454/02. London, 2003.
  • 35
    EMEA. Note for guidance on clinical investigation of anti-anginal medicinal products in stable angina pectoris. CPMP/EWP/234/95. London, 1996.
  • 36
    EMEA. Note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women. CPMP/EWP/18/01 draft. London, 2001.
  • 37
    EMEA. Note for guidance on clinical investigation of drugs used in weight control. CPMP/EWP/281/96. London, 1997.
  • 38
    EMEA. Note for guidance on the clinical investigation of medicinal products for treatment of migraine. CPMP/EWP/788/01. London, 2001.
  • 39
    Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999;2: 11327.
  • 40
    Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 2000;9: 887900.
  • 41
    Chassany O, Sagnier P, Marquis P, et al. For the European Regulatory Issues on Quality of Life Assessment Group. Patient-reported outcomes: the example of health-related quality of life—a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J 2002;36: 20918.
  • 42
    The Health-Related Subjective Measurements Working Group of the Societe Francaise de Statistique/Biopharmacie & Sante. The European regulatory issues on quality of life assessment group guidance: some critical comments. Drug Inf J 2003;37: 3556.
  • 43
    Council Directive 92/28/EEC of 31 March 1992 on the advertising of medicinal products for human use. OJ 30041992;113: 001318.
  • 44
    EMEA. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation in medicinal products. EMEA/CHMP/EWP/139391/204. London, 2004.